phrykt

Biogen (BIIB) cash: $3B

Biogen held $3B in cash and cash equivalents on Dec 31, 2025, up 26.7% from $2.4B a year earlier.

From Biogen's filings with the SEC · Read the filing · BIIB stock page

Biogen cash by year

$2.3B2021$3.4B2022$1B2023$2.4B2024$3B2025

#204 of 4,171 US companies by cash · See the full ranking

Year endedCashChange
Dec 31, 2025$3B+27%
Dec 31, 2024$2.4B+126%
Dec 31, 2023$1B-69%
Dec 31, 2022$3.4B+51%
Dec 31, 2021$2.3B–

Cash of similar companies

Companies in the same industry as Biogen, by SEC industry code, with the closest cash. Each name opens the same page for that company.

CompanyCash, latest yearYear ended
Amgen$9.1BDec 31, 2025
Gilead Sciences$7.6BDec 31, 2025
Biogen$3BDec 31, 2025
Moderna$2.6BDec 31, 2025
Immunovant$995MDec 31, 2025
Qiagen$839MDec 31, 2025
Recursion Pharmaceuticals$743MDec 31, 2025

Questions and answers

What is Biogen's cash?

Biogen held $3B in cash and cash equivalents on Dec 31, 2025, up 26.7% from $2.4B a year earlier.

Numbers as reported in Biogen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology